

018 / ACTIV: A Multicenter, Adaptive, Randomized, Controlled Trial Platform To Evaluate Safety and Efficacy of Strategies and Treatments for Hospitalized Patients with Respiratory Infections

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- admitted to the hospital with symptoms of respiratory infection - positive test for SARS-CoV2 infection (COVID) within the prior 14 days - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- expect to be discharged in the next 24 hours - unable to swallow tablets - women who are pregnant or breast feeding - liver or kidney failure - men and women who are unwilling to use contraception to prevent pregnancy

Conditions & Interventions

Interventions:

Drug: Shionogi Protease Inhibitor (S-217622), Drug: placebo

Conditions:

Infectious Diseases, Respiratory System

Keywords:

Clinics and Surgery Center (CSC), COVID, hospitalized, inpatient, pneumonia, respiratory infection

More Information

Description: We are studying an investigational medicine for treatment of people in the hospital with COVID-19. This medicine is investigational because it can only be used in research. We are trying to find out if this investigational medicine is effective when given in addition to the current standard treatment for COVID-19. We are also trying to make sure it is safe for people who are sick in the hospital to take. The treatment being tested in this study is not yet approved by the U.S. Food and Drug Administration (FDA) or any other national government agency.

Study Contact: Michelle Snyder - snyde003@umn.edu

Principal Investigator: Mahsa Abassi

Phase: PHASE3

IRB

Number: SITE00001781

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.